RU2011107443A - Индаценовые соединения, фармацевтическая композиция и лекарственное средство на их основе, способ их получения и способ лечения или профилактики состояний, связанных с нарушением функционирования систем, регулируемых мелатонином, с их помощью - Google Patents

Индаценовые соединения, фармацевтическая композиция и лекарственное средство на их основе, способ их получения и способ лечения или профилактики состояний, связанных с нарушением функционирования систем, регулируемых мелатонином, с их помощью Download PDF

Info

Publication number
RU2011107443A
RU2011107443A RU2011107443/04A RU2011107443A RU2011107443A RU 2011107443 A RU2011107443 A RU 2011107443A RU 2011107443/04 A RU2011107443/04 A RU 2011107443/04A RU 2011107443 A RU2011107443 A RU 2011107443A RU 2011107443 A RU2011107443 A RU 2011107443A
Authority
RU
Russia
Prior art keywords
group
methyl
fluoro
indacen
aza
Prior art date
Application number
RU2011107443/04A
Other languages
English (en)
Russian (ru)
Inventor
Антонио ГУЛЬЕТТА (IT)
Антонио ГУЛЬЕТТА
Альберт ПАЛОМЕР (ES)
Альберт Паломер
Хосе Л. ФАЛЬКО (ES)
Хосе Л. ФАЛЬКО
Original Assignee
Феррер Интернасионал С.А. (ES)
Феррер Интернасионал С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41138660&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2011107443(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Феррер Интернасионал С.А. (ES), Феррер Интернасионал С.А. filed Critical Феррер Интернасионал С.А. (ES)
Publication of RU2011107443A publication Critical patent/RU2011107443A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
RU2011107443/04A 2008-07-30 2009-07-29 Индаценовые соединения, фармацевтическая композиция и лекарственное средство на их основе, способ их получения и способ лечения или профилактики состояний, связанных с нарушением функционирования систем, регулируемых мелатонином, с их помощью RU2011107443A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161485 2008-07-30
EP08161485.1 2008-07-30

Publications (1)

Publication Number Publication Date
RU2011107443A true RU2011107443A (ru) 2012-09-10

Family

ID=41138660

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011107443/04A RU2011107443A (ru) 2008-07-30 2009-07-29 Индаценовые соединения, фармацевтическая композиция и лекарственное средство на их основе, способ их получения и способ лечения или профилактики состояний, связанных с нарушением функционирования систем, регулируемых мелатонином, с их помощью

Country Status (16)

Country Link
US (1) US8227501B2 (cg-RX-API-DMAC7.html)
EP (1) EP2350088A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011529477A (cg-RX-API-DMAC7.html)
KR (1) KR20110041495A (cg-RX-API-DMAC7.html)
CN (1) CN102112480A (cg-RX-API-DMAC7.html)
AR (1) AR075262A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009275918A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0916395A2 (cg-RX-API-DMAC7.html)
CA (1) CA2731405A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011000184A1 (cg-RX-API-DMAC7.html)
MX (1) MX2011001062A (cg-RX-API-DMAC7.html)
PE (1) PE20110208A1 (cg-RX-API-DMAC7.html)
RU (1) RU2011107443A (cg-RX-API-DMAC7.html)
TW (1) TW201018695A (cg-RX-API-DMAC7.html)
UY (1) UY32016A (cg-RX-API-DMAC7.html)
WO (1) WO2010012789A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103601683B (zh) * 2010-04-16 2016-03-30 中国科学院上海药物研究所 苯并杂环类化合物及其制备方法和用途
AR091699A1 (es) * 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
CN104109143B (zh) * 2013-04-22 2018-04-27 上海阳帆医药科技有限公司 一类褪黑激素(mt1-mt2)受体激动剂及其制备方法与用途
CN104326916B (zh) * 2014-10-10 2017-09-22 青岛农业大学 2‑氟‑4‑烯丙基‑6‑硝基苯酚与2‑氟‑4‑硝基‑6‑烯丙基苯酚的联合制备及用途
MY203941A (en) * 2016-06-17 2024-07-25 Daewoong Pharmaceutical Co Ltd Method for producing diphenylmethane derivative
CA3244229A1 (en) * 2021-12-24 2023-06-29 Psylo Pty Ltd COMPOUNDS
KR20240044190A (ko) * 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 결정형 및 이의 제조방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600723A (en) 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
EP0126630B1 (en) 1983-05-18 1987-09-16 Monash University The use of melatonin for the manufacture of a medicament
WO1989001472A1 (en) 1987-08-17 1989-02-23 Nelson Research & Development Co. Melatonin analogues
FR2680366B1 (fr) 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
WO1997001539A1 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. 4-acylamino(halogeno) alkyl-quinoline derivatives, their preparation and their use as melatonin agonists
US5732360A (en) 1995-09-08 1998-03-24 At & T Wireless Services And Atmel Corp Mobile telecommunication device and method used for changing wireless communication between base stations of different kinds
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
WO1997032871A1 (en) 1996-03-08 1997-09-12 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
FR2771739B1 (fr) 1997-11-28 2001-04-20 Adir Nouveaux composes naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2784375B1 (fr) 1998-10-12 2000-11-24 Adir Nouveaux derives cycliques a chaine cycloalkylenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2793793B1 (fr) 1999-05-19 2004-02-27 Adir Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU6595100A (en) 1999-08-20 2001-03-19 Takeda Chemical Industries Ltd. Percutaneous absorption agents
FR2799757B1 (fr) 1999-10-15 2001-12-14 Adir Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6737431B2 (en) 2002-03-12 2004-05-18 Bristol-Myers Squibb Company Benzoxazole derivatives as novel melatonergic agents
BR0312175A (pt) 2002-06-21 2005-04-05 Suven Life Sciences Ltd Composto, composição farmacêutica, uso de um composto, método para o tratamento e método para reduzir a morbidez e a mortalidade associadas com o excesso de peso
US6908931B2 (en) 2003-04-10 2005-06-21 Bristol-Myers Squibb Company Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists
WO2005062992A2 (en) 2003-12-23 2005-07-14 Abraxis Bioscience, Inc Substituted melatonin derivatives, process for their preparation, and methods of use

Also Published As

Publication number Publication date
JP2011529477A (ja) 2011-12-08
MX2011001062A (es) 2011-03-24
CL2011000184A1 (es) 2011-09-16
AR075262A1 (es) 2011-03-23
CA2731405A1 (en) 2010-02-04
WO2010012789A1 (en) 2010-02-04
US8227501B2 (en) 2012-07-24
AU2009275918A1 (en) 2010-02-04
BRPI0916395A2 (pt) 2016-02-16
EP2350088A1 (en) 2011-08-03
KR20110041495A (ko) 2011-04-21
US20110144178A1 (en) 2011-06-16
CN102112480A (zh) 2011-06-29
PE20110208A1 (es) 2011-03-28
UY32016A (es) 2010-01-29
TW201018695A (en) 2010-05-16

Similar Documents

Publication Publication Date Title
TWI727362B (zh) 氯胺酮衍生物及其組成物
AU2003208538B2 (en) Amino acids with affinity for the alpha-2-delta-protein
CA2177773C (fr) Nouveaux aryl(alkyl)propylamides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN102164488B (zh) 有益于治疗中枢神经系统疾病和病症的新化合物
NZ590951A (en) Cyclic nucleotide phosphodiesterases PDE10 inhibitors for treating neurological disorders
US5552418A (en) Trisubstituted Naphthylalkylamides
JP2011529477A5 (cg-RX-API-DMAC7.html)
CA2529320A1 (en) Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases
IL197135A (en) The phenoxyphenylacetic acid derivatives are preserved in position 4, preparations containing them, their uses and methods for preparing them
AR063945A1 (es) Acidos carboxilicos inhibidores de la metalproteinasa matriz.
JP2007529446A5 (cg-RX-API-DMAC7.html)
CN1067678C (zh) 新烷基化杂环化合物,这类化合物的制备方法以及含这类化合物的药物组合物
CN102482203A (zh) 碳环glyt1受体拮抗剂
JPH08176080A (ja) 新規なメラトニン作動薬
US7112610B2 (en) Methods for using amino acids with affinity for the α2δ-protein
ES2650139T3 (es) Compuestos 3-fenilsulfanilmetil-biciclo[3.1.0]hexano 4-sustituidos como antagonistas de mGluR 2/3
JP2011511053A (ja) ボリノスタットの新規な製造方法
EA004984B1 (ru) Способ стереоселективного синтеза циклических аминокислот
OA13258A (en) Amino acids with affinity for the alpha2delta-protein.
WO2010055911A1 (ja) ビフェニルアセトアミド誘導体
US20100016403A1 (en) Use of d-serine derivatives for the treatment of anxiety disorders
RU2010120847A (ru) Соединения индолина, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний
JP2016169166A (ja) 1‐アミノ‐3,5‐ジメチルアダマンタン塩酸塩の製造方法
EP4499603A1 (en) Benzamide enaminone derivatives and methods of use thereof
IL185010A0 (en) Nk1 antagonists

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20130604